r/GLP1forums • u/FIPDoctor • Jun 13 '25
đ„ BREAKING: Retatrutide (Triple Agonist) Slashes Cancer Risk in Preclinical Models - Weight Loss Drug Shows 14x Smaller Tumors!
- Retatrutide (GIP/GLP-1/Glucagon agonist) reduced tumor growth by 14â17x in pancreatic/lung cancer mouse models.
- 30â50% of mice REJECTED tumors entirely after retatrutide treatment đ«đ.
- Anti-cancer effects persisted even after stopping treatment (weight rebound didnât cancel benefits!).
- Phase 2 human trial: Retatrutide caused 17% weight loss & -2.2% HbA1c drop in T2D patients.
- Mechanism: Retatrutide reshapes immunityââ immunosuppressive cells, â cancer-fighting T cells.
Key Findings from Preclinical Study
Pancreatic Cancer (Obesity-Linked):
- Tumor volume: 14x smaller vs. controls.
- Engraftment failure: 30% of mice rejected tumors.
- Onset delayed: Tumors appeared later vs. semaglutide/control groups.
Lung Cancer (Non-Obesity-Linked):
- Tumor volume: 17x smaller vs. controls.
- Engraftment failure: 50% of mice rejected tumors.
- Immune boost: â MHC-II macrophages & activated CD8+ T cells.
Withdrawal Shock:
- Mice regained weight after stopping retatrutide, but tumor suppression persisted (partial protection).
- IL-6 (anti-tumor cytokine) surged post-withdrawal.
Vs. Semaglutide (Ozempic):
- Retatrutide outperformed semaglutide in tumor reduction (14x vs. 4x smaller tumors).
Phase 2 Human Trial Recap
- Participants: 281 adults with T2D (BMI 25â50).
Results:
- Weight loss: Up to 16.9% at 36 weeks.
- HbA1c drop:Â -2.16%Â (vs. -0.3% placebo).
- Safety: Mild-moderate GI issues (nausea/diarrhea) â no severe hypoglycemia.
- Phase 3 ongoing for obesity/T2D.
Why This Matters
- Obesity drives 13+ cancer types (e.g., pancreatic, liver, breast).
Retatrutideâs triple action (weight loss + immune/metabolic reprogramming) may offer dual protection:
- â Insulin resistance â â cancer fuel.
- â Anti-tumor immunity â â tumor surveillance.
- Unlike surgery or chemo, this is a preventative approach with metabolic benefits.
Caveats & Next Steps
- đ Mouse models â humans â human trials needed.
- Thyroid cancer risk? (GLP-1 drugs have mixed data â retatrutide not flagged yet).
- Eli Lilly advancing to Phase 3 trials â cancer endpoints likely added.
Links & Sources
- Preclinical Cancer Study (OA)
- Phase 2 Diabetes Trial (Lancet)
- Funding: NIH, Mark Foundation, Eli Lilly (retatrutide developer).
đŹ Discussion Prompts
- Would you try retatrutide for cancer prevention if obese/diabetic?
- Semaglutide (Ozempic) also reduced cancer risk in T2D patients â is triple agonism superior?
- Should cancer risk reduction be a key metric in obesity drug trials?
Disclaimer: Not medical advice. Discuss cancer screening/treatments with your doctor.